Evaluation of the HER/PI3K/AKT Family Signaling Network as a Predictive Biomarker of Pathologic Complete Response for Patients With Breast Cancer Treated With Neratinib in the I-SPY 2 TRIAL BaSyc is ...
As rare disease trials face persistent feasibility challenges, Bayesian designs are gaining momentum by enabling more ...
In this video interview, David Morton, PhD, director of biostatistics at Certara, explains how regulatory momentum is ...
An innovative approach to a phase II clinical trial aims to test the effects of multiple targeted treatments simultaneously in participants in the UK National Lung Matrix Trial. The design makes it ...
Health care is undergoing an important and well-needed shift from a one-size-fits-all approach to more personalized, precise, patient-focused care. A similar approach needs to be implemented at scale ...
The US Food and Drug Administration (FDA) last week finalized guidance on adaptive clinical trial designs for drugs and biologics. The 33-page guidance, which finalizes a draft version released for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results